罗欣药业
(002793)
| 流通市值：44.20亿 | | | 总市值：44.26亿 |
| 流通股本：10.86亿 | | | 总股本：10.88亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,679,620,881.67 | 1,147,454,455.61 | 582,726,187.11 | 2,273,457,651.02 |
| 营业收入 | 1,679,620,881.67 | 1,147,454,455.61 | 582,726,187.11 | 2,273,457,651.02 |
| 二、营业总成本 | 1,580,861,770.29 | 1,070,756,842.95 | 559,455,929.53 | 2,515,661,813.36 |
| 营业成本 | 705,597,448.01 | 452,897,192.53 | 227,208,891.61 | 1,144,712,765 |
| 税金及附加 | 21,865,876.17 | 13,526,241.39 | 5,949,634.78 | 32,990,744.14 |
| 销售费用 | 604,137,821.45 | 432,037,992.26 | 225,295,313.85 | 923,686,164.76 |
| 管理费用 | 168,285,372 | 117,304,458.48 | 68,340,548.27 | 264,894,460.09 |
| 研发费用 | 48,268,174.24 | 32,046,285.55 | 18,232,707.52 | 91,604,963.32 |
| 财务费用 | 32,707,078.42 | 22,944,672.74 | 14,428,833.5 | 57,772,716.05 |
| 其中:利息费用 | 35,581,122.84 | 24,355,280.9 | 13,482,927.37 | 55,590,566.27 |
| 其中:利息收入 | 3,522,898.46 | 2,138,297.02 | 728,222.04 | 2,552,781.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -35,351,860.47 |
| 加:投资收益 | 6,201,043.41 | 13,448,385.21 | 15,790,553.23 | -13,320,728.13 |
| 资产处置收益 | 505,205.47 | 330,975.26 | 161,326.31 | 3,084,463.82 |
| 资产减值损失(新) | -24,358,680.11 | -23,985,363 | -5,720,344.62 | -102,221,116.52 |
| 信用减值损失(新) | 7,768,072.8 | 5,118,178.8 | 5,779,033.12 | 46,886,098.45 |
| 其他收益 | 7,421,826.49 | 6,955,748.22 | 2,633,294.08 | 42,876,798.74 |
| 四、营业利润 | 96,296,579.44 | 78,565,537.15 | 41,914,119.7 | -300,250,506.45 |
| 加:营业外收入 | 3,842,897.95 | 3,186,180.44 | 1,470,738.15 | 14,874,611.8 |
| 减:营业外支出 | 8,451,233.8 | 8,261,489.27 | 688,777.31 | 5,496,073.93 |
| 五、利润总额 | 91,688,243.59 | 73,490,228.32 | 42,696,080.54 | -290,871,968.58 |
| 减:所得税费用 | 29,348,079.3 | 20,257,091.2 | 13,700,614.92 | -6,345,798.35 |
| 六、净利润 | 62,340,164.29 | 53,233,137.12 | 28,995,465.62 | -284,526,170.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 62,340,164.29 | 53,233,137.12 | 28,995,465.62 | -284,526,170.23 |
| 终止经营净利润 | - | - | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 61,454,932.53 | 49,934,125.4 | 24,150,076.94 | -288,580,202.99 |
| 少数股东损益 | 885,231.76 | 3,299,011.72 | 4,845,388.68 | 4,054,032.76 |
| 扣除非经常损益后的净利润 | 36,154,752.15 | 30,368,625.32 | 3,964,563.56 | -288,047,268.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.05 | 0.02 | -0.27 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.02 | -0.27 |
| 八、其他综合收益 | -1,054,613.1 | -4,409,190.25 | -1,558,099.61 | 23,563,654.64 |
| 归属于母公司股东的其他综合收益 | -1,050,972.15 | -4,393,967.96 | -1,552,720.43 | 23,482,303.48 |
| 九、综合收益总额 | 61,285,551.19 | 48,823,946.87 | 27,437,366.01 | -260,962,515.59 |
| 归属于母公司股东的综合收益总额 | 60,403,960.38 | 45,540,157.44 | 22,597,356.51 | -265,097,899.51 |
| 归属于少数股东的综合收益总额 | 881,590.81 | 3,283,789.43 | 4,840,009.5 | 4,135,383.92 |
| 公告日期 | 2026-10-27 | 2026-08-21 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |